HDL biology
Psyllium plus plant sterols lowers CETP activity by 11% and raises LDL receptor abundance by 26%, explaining part of its LDL-lowering mechanism (J Nutr 2007)
Original title: A combination of psyllium and plant sterols alters lipoprotein metabolism in hypercholesterolemic subjects by modifying the intravascular processing of lipoproteins and increasing LDL uptake
Building on prior findings that psyllium plus plant sterols (PSY+PS) lowers LDL cholesterol in 33 hypercholesterolemic subjects in a randomized, double-blind crossover trial, this study examined the intravascular and molecular mechanisms. PSY+PS intake decreased cholesterol in LDL-1 (2.46 +/- 0.66 to 2.26 +/- 0.46 mmol/L) and LDL-2 (0.63 +/- 0.24 to 0.54 +/- 0.27 mmol/L, P < 0.05 for both), increased LDL peak size (27.3 +/- 0.8 to 27.5 +/- 0.6 nm, P < 0.05), and decreased the prevalence of atherogenic LDL pattern B from 27% to 18% (P < 0.05). Cholesteryl ester transfer protein activity was 11% lower during the test period (P < 0.05), and LDL receptor abundance in circulating mononuclear cells was 26% higher (P < 0.03), indicating the hypocholesterolemic action of PSY+PS involves both altered intravascular lipoprotein processing and increased LDL receptor-mediated uptake.
Original abstract
We previously demonstrated that a diet therapy involving consumption of 7.28 g psyllium (PSY) and 2 g of plant sterols (PS) per day reduced LDL cholesterol from 3.6 +/- 0.7 to 3.1 +/- 0.8 mmol/L (P < 0.01) and decreased the number of intermediate density lipoprotein particles and the smaller LDL and HDL subfractions in hypercholesterolemic individuals (n = 33). The study design was a randomized double blind crossover. Subjects consumed either 2 test cookies containing PSY+PS or 2 placebo cookies for 1 mo with a 3-wk wash out between treatments. To explore mechanisms of the lipid-lowering effects of combined PSY+PS, we present data related to intravascular and molecular regulation. Intake of PSY+PS decreased the cholesterol concentration in LDL-1 from 2.46 +/- 0.66 to 2.26 +/- 0.46 mmol/L and in LDL-2 from 0.63 +/- 0.24 to 0.54 +/- 0.27 mmol/L (P < 0.05) in the test compared with the placebo period. An increase in LDL peak size from 27.3 +/- 0.8 to 27.5 +/- 0.6 nm (P < 0.05) and a decrease in the prevalence of LDL pattern B from 27 to 18% (P < 0.05) also occurred during the PSY+PS period. Cholesteryl ester transfer protein activity was 11% lower (P < 0.05) during the test period. Notably, the abundance of the LDL receptor in circulating mononuclear cells as measured by real time PCR was 26% higher during the test compared with the placebo period (P < 0.03). These results indicate that the hypocholesterolemic action of PSY and PS can be explained in part by modifications in the intravascular processing of lipoproteins and by increases in LDL receptor-mediated uptake.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.